nintedanib

Also Known As:

BIBF 1120; BIBF-1120; BIBF1120; Nintedanib esylate; Ofev; Vargatef; METHYL (3Z)-3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLIDENE)-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE

Networked: 1020 relevant articles (166 outcomes, 328 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - nintedanib: 1020

Experts

1.	Stowasser, Susanne: 44 articles (01/2022 - 05/2014)
2.	Richeldi, Luca: 43 articles (01/2022 - 09/2011)
3.	Maher, Toby M: 24 articles (05/2022 - 01/2013)
4.	Kolb, Martin: 24 articles (01/2022 - 05/2014)
5.	Cottin, Vincent: 22 articles (04/2022 - 05/2014)
6.	Quaresma, Manuel: 21 articles (01/2022 - 09/2015)
7.	Schlenker-Herceg, Rozsa: 21 articles (01/2022 - 05/2014)
8.	Wollin, Lutz: 21 articles (11/2021 - 05/2014)
9.	Kaiser, Rolf: 21 articles (10/2020 - 01/2010)
10.	Kreuter, Michael: 20 articles (11/2022 - 01/2015)

Related Diseases

1.	Idiopathic Pulmonary Fibrosis 01/01/2019 - "Although the beneficial effects of nintedanib were demonstrated for human idiopathic pulmonary fibrosis, its efficacy for PAH is still unclear. " 05/15/2021 - "Nintedanib is effective for treating idiopathic pulmonary fibrosis (IPF), but some patients may exhibit a suboptimal response and develop on-treatment acute exacerbation (AE-IPF), hepatic injury, or mortality. " 04/10/2017 - "Is nintedanib effective for idiopathic pulmonary fibrosis?" 01/15/2016 - "Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis." 12/01/2016 - "Although nintedanib is attracting much attention as a new treatment option for patients with idiopathic pulmonary fibrosis (IPF), the clinical evidence is limited mainly to the results from the dose-deciding phase II TOMORROW trial and phase III INPULSIS trials, which evaluated efficacy and safety of nintedanib for patients with IPF, prespecified subgroup analyses, pooled analyses and meta-analyses derived from those trials. "
2.	Interstitial Lung Diseases (Interstitial Lung Disease) 01/01/2023 - "The SENSCIS® trial demonstrated a significant reduction of lung function decline in patients with SSc-associated interstitial lung disease (SSc-ILD) treated with nintedanib, but no significant effect on health-related quality of life (HRQoL). " 10/01/2021 - "The efficacy of nintedanib in progressive fibrosing interstitial lung diseases (ILDs) was demonstrated in the randomised, double-blind, placebo-controlled INBUILD trial. " 12/01/2016 - "The literature search was undertaken using Pub Med. Expert commentary: It is unknown whether the efficacy of nintedanib in patients enrolled in the clinical trials will be the same for the entire spectrum of patients, including patients unfit for the clinical trials due to age, severity, timing of IPF diagnosis or diagnosis of interstitial pneumonias other than IPF. " 01/01/2022 - "It is expected that these findings will contribute to the development of improved nintedanib strategies for the treatment of progressive fibrosing interstitial lung diseases." 01/01/2023 - "In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. "
3.	Fibrosis (Cirrhosis) 07/01/2019 - "Our data demonstrate significant antifibrotic efficacy of nintedanib in SSc-ILD LF suggesting that nintedanib has the potential not only to prevent but also to reverse the increased activity of LF consequently attenuating excessive lung fibrosis observed in SSc-ILD." 09/01/2014 - "High-dose nintedanib improved the quality of life, slowed the progression of lung fibrosis and the decline of lung function, and reduced the rate of exacerbations in individuals with mild and moderate IPF. " 01/01/2022 - "Further randomized controlled trials are needed to determine the efficacy of nintedanib for treatment of patients with post-COVID-19 lung fibrosis. " 01/01/2020 - "In agreement, a recent controlled trial suggests efficacy of nintedanib, an antifibrotic drug, in patients with progressive lung fibrosis, including RA-ILD. " 01/01/2022 - "This study aimed to evaluate the effect of nintedanib on patients' post-COVID-19 lung fibrosis. "
4.	Neoplasms (Cancer) 02/01/2020 - "Although Nintedanib treatment in late stages of tumor growth has shown some good results, it is noteworthy that the drug presents the best tissue response when administered in the early stages of disease development. " 06/01/2010 - "Expert opinion on the promising results obtained in Phase I studies demonstrating that BIBF 1120 is well tolerated in patients with advanced solid tumors will be provided. " 05/01/2023 - "Post-SRS administration of nintedanib for IPF may have provided some anti-tumor efficacy for lung SCC and may mitigate the adverse effects of SRS. " 01/01/2022 - "Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells." 01/01/2019 - "Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer."
5.	Disease Progression 09/29/2023 - "Conclusions: The use of nintedanib alone and in combination with mycophenolate in patients with SSc-ILD is associated with a significant reduction in disease progression compared to placebo but at the cost of increased gastrointestinal side effects and treatment discontinuation. " 03/01/2018 - "Data from extension trials indicate that nintedanib continues to slow disease progression for up to 3 years and is similarly effective in patients with mild and severe impairment of lung function. " 01/01/2018 - "Real-world experiences also support the findings of previously conducted clinical trials and show that nintedanib is effective for the management of IPF and is associated with reducing disease progression. " 07/01/2014 - "The INPULSIS™ trials will determine the efficacy of nintedanib in patients with IPF, including its impact on disease progression as defined by decline in FVC, acute exacerbations and health-related quality of life. " 01/07/2023 - "Significant associations between lower BMI values and adverse outcomes were reported in 10 out of 21 studies on mortality, four out of six studies on disease progression or hospitalization, and two out of three studies on nintedanib tolerability. "

Related Drugs and Biologics

1.	pirfenidone
2.	Docetaxel (Taxotere)
3.	Tyrosine Kinase Inhibitors
4.	Bleomycin (Blenoxane)
5.	nintedanib
6.	Phosphotransferases (Kinase)
7.	Antifibrotic Agents
8.	Carboplatin (JM8)
9.	Pemetrexed (MTA)
10.	Sorafenib (BAY 43-9006)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Aftercare (After-Treatment)
5.	Drug Tapering